ALKERMES | ALKS - Capital Ordinaire





Capital Ordinaire Changement Date
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
J&J USD 2.41B 1.74M 2025-12
Malin Corporation EUR 200K 0 2024-12
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Otsuka Holdings JPY 527.31M 824K 2026-03
Ovoca Bio EUR 29.49M 18.43M 2025-06
Pfizer USD 5.7B 13M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03